- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Chronic Lymphocytic Leukemia | Clinical
FDA Approves New Tablet Form for Acalabrutinib
August 05, 2022
Acalabrutinib’s new tablet formulation has been granted FDA approval for all current indications, including adult patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and relapsed or refractory mantle cell lymphoma.
Zanubrutinib Displays PFS Benefit Over Bendamustine/Rituximab in CLL and SLL
August 01, 2022
In the first comparison of zanubrutinib vs chemoimmunotherapy, zanbrutinib was shown to improve progression-free survival in patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma, and may be less toxic.
MB-106 Treatment Appears Safe and Effective in R/R B-Cell Malignancies
July 22, 2022
Mazyar Shadman, MD, MPH, discusses the results of his research on MB-106 as treatment for patients with relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Burger Details the Data to Help Choose Treatment in Chronic Lymphocytic Leukemia
July 03, 2022
During a Targeted Oncology case-based roundtable event, Jan A. Burger, MD, PhD, discussed data supporting the use of ibrutinib, acalabrutinib, and zanubrutinib for first-line treatment of chronic lymphocytic leukemia.
Ibrutinib/Venetoclax May Decrease Development of Resistance Mutations in Patients With CLL
June 29, 2022
Findings from an analysis of the CAPTIVATE study imply that ibrutinib plus venetoclax may allow for effective subsequent retreatment with ibrutinib and/or venetoclax and enhance clinical benefit.
Roundtable Discussion: Exploring Frontline CLL Treatment With BTK Inhibitors
June 24, 2022
During a Targeted Oncology case-based roundtable event, John N. Allan, MD, discussed the factors for choosing treatment for chronic lymphocytic leukemia with a Bruton tyrosine kinase inhibitor.
Phase 1/2 Study Examines MB-106 in Various Positive B-cell Malignancies
June 20, 2022
Mazyar Shadman, MD, MPH, discusses the phase 1/2 clinical trial of MB-106 for patients with CD20 positive B-cell malignancies.
Roundtable Discussion: O’Brien and Participants Compare Therapies They Would Use in CLL
June 17, 2022
During a Targeted Oncology case-based roundtable event, Susan O'Brien, MD, discussed the case of a 71-year-old woman newly diagnosed with chronic lymphocytic leukemia.
Interpreting the Results of the ELEVATE-TN Trial for Treatment-Naive CLL
June 10, 2022
Nakhle Saba, MD, discusses the significance of the key findings of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab for patients with chronic lymphocytic leukemia.
Acalabrutinib-Based Regimens Continue to Top Obinutuzumab Plus Chemotherapy in Treatment-Naïve CLL
June 04, 2022
With roughly 5 years of follow-up, outcomes were more favorable with acalabrutinib with or without obinutuzumab vs obinutuzumab and chlorambucil in patients with treatment-naïve chronic lymphocytic leukemia.